Drugs / Quabodepistat
Quabodepistat
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07314320 | Nov → Dec 2023 | — | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT07542847 | Sep → Nov 2022 | — | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03678688 | Oct 2018 → Feb 2022 | pulmonary tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06114628 | Jan 2024 → Feb 2027 expected | pulmonary tuberculosis | University College, London | Recruiting | No outcome recorded |
| Phase 2 | NCT05971602 | Jul 2023 → Feb 2025 | pulmonary tuberculosis | Gates Medical Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT05221502 | Apr 2022 → Apr 2024 | pulmonary tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07209761 | Oct 2025 → May 2027 expected | pulmonary tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-06 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Announces First Participants Enrolled in Phase 3 Clinical Trial Evaluating Investigational Compound Quabodepistat for Drug-resistant Pulmonary Tuberculosis otsuka.co.jp ↗ |
| 2025-11-06 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Announces First Participants Enrolled in Phase 3 Clinical Trial Evaluating Investigational Compound Quabodepistat for Drug-resistant Pulmonary Tuberculosis otsuka-us.com ↗ |
| 2021-08-10 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaquiline otsuka.co.jp ↗ |
| 2021-08-09 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaquiline otsuka-us.com ↗ |
| 2018-01-29 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Awarded Grant to Advance Development of Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid otsuka.co.jp ↗ |
| 2018-01-29 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Awarded Grant to Advance Development of Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid otsuka-us.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quabodepistat | “Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label,...” PMID 38243296 ↗ Jan 20243“Quabodepistat (formerly OPC-167832) showed potent activity in preclinical studies and in the first stage of an early bactericidal activity study in adults with smear-positive,...” PMID 39612928 ↗ Nov 2024 “Bedaquiline 400 mg once daily for 2 weeks then 100 mg once daily for 15 weeks + Pretomanid 200 mg QD for 17 weeks + Quabodepistat 30 mg once daily for 17 weeks + Moxifloxacin...” NCT07209761 ↗ |
| Known as | OPC-167832 | “Quabodepistat (formerly OPC-167832) showed potent activity in preclinical studies and in the first stage of an early bactericidal activity study in adults with smear-positive,...” PMID 39612928 ↗ Nov 2024 |
| Known as | QBS | “Quabodepistat (QBS) is a newly discovered inhibitor of decaprenylphosphoryl-β-D-ribose-2'-oxidase, an essential enzyme for Mycobacterium tuberculosis to synthesize key...” PMID 38243296 ↗ Jan 2024 |
| Action | Inhibit | “inhibitor of decaprenylphosphoryl-β-D-ribose-2'-oxidase” PMID 38243296 ↗ Jan 2024 |
| Modality | Small molecule | — CHEMBL5095080 ↗ |
| Route | Oral | “This trial will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of multiple oral doses of OPC-167832 in participants with uncomplicated, smear-positive,...” NCT03678688 ↗ |